Rational treatment of panic disorder with antidepressants

Annals of Clinical Psychiatry

Volumn 10, Issue 4, 1998, Pages 185-195

  Mavissakalian, Matig R ^a   Ryan, Martin T ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Agoraphobia; Imipramine; Maintenance therapy; Panic disorder; Selective serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR;

AGORAPHOBIA; DRUG CHOICE; DRUG EFFICACY; HUMAN; PANIC; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

AGORAPHOBIA; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIPRAMINE; MALE; PANIC DISORDER; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0032453359     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022302414638     Document Type: Review

References (29)

1. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. Washington: American Psychiatric Association Press; 1994
2. Noyes R, Garvey MJ, Cook BL, Samuelson L: Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: Results of a naturalistic follow-up study. J Clin Psychiat 1989; 50:163-169
3. Goisman RM, Warshaw MG, Peterson LG, et al.: Panic, agoraphobia, and panic disorder with agoraphobia. J. Nerv Ment Dis 1994; 182:72-79
4. Otto MW, Pollack MH, Sabatino SA: Maintenance of remission following cognitive behavior therapy for panic disorder: Possible deleterious effects of concurrent medication treatment. Behav Ther 1996; 27:473-482
5. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiat 1991; 48:851-855
6. Mavissakalian M, Perel JM: Imipramine in panic disorder with agoraphobia: Dose ranging and plasma level-response relationships. Am J Psychiat 1995; 152:673-682
7. Mavissakalian M, Perel JM: Clinical experiments in maintenance and discontinuation of imipramine in panic disorder with agoraphobia. Arch Gen Psychiat 1992; 49:318-323
8. Mavissakalian M, Perel JM: The relationship of plasma imipramine and N-desmethylimipramine to response in panic disorder. Psychopharmacol Bull 1996; 32:143-147
9. Gentil V, Lotufo-Neto F, Andrade L, Cordas T, Bernik M, Ramos R, Maciel L, Miyakawa E, Gorenstein C: Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine. J Psychopharm 1993; 7:316-324
10. den Boer JA, Westenberg H: Effect of serotonin and noradrenaline uptake inhibitor in panic disorders: A double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1984; 3:59-74
11. Mavissakalian M, Perel JM, Talbott-Green M, Sloan C: Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. Biol Psychiat 1998; 43:848-854
12. Bakish D, Hooper C, Filteau MJ, et al.: A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 1996; 32:135-141
13. Magnani K, Amore M: Panic disorder. A long term treatment study: Fluoxetine vs imipramine. Biol Psychiat 1997; 42:17S
14. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T: The effect of citalopram in panic disorder. Br J Psychiat 1997; 170:549-553
15. Mathews AM, Gelder MG, Johnston DW, eds.: Agoraphobia: Nature and Treatment. New York: Guilford, 1981
16. Mavissakalian M, Perel JM: Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiat 1992; 149:1053-1058
17. Mavissakalian M, Perel JM, de Groot C: Imipramine treatment of panic disorder with agoraphobia: The second time around. J Psychol Res 1993; 27:61-68
18. Michelson D, Lydiard RB, Pollack MH, Tamura R, Tepner R: Fluoxetine treatment of panic disorder: A randomized, placebo-controlled, multi-center trial. Biol Psychiat 1998; 43:93S
19. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP: Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiat 1998; 155:36-42
20. Londborg PD, Wolkow R, Smith WT, et al.: Sertraline in the treatment of panic disorder. Br J Psychiat 1998; 173:54-60
21. Maier W, Roth M, Argyle N, et al.: Avoidance behavior: A predictor of the efficacy of pharmacotherapy in panic disorder? Eur Arch Psychiat Clin Neurosci 1991; 241:151-158
22. Data on file, SmithKline Beecham Pharmaceuticals
23. Michelson D, Lydiard RB, Pollack M, Tamura R, Tepner R, Tollefson G: Long-term treatment in panic disorder: Randomization of acute fluoxetine responders to continued treatment with fluoxetine or placebo. Biol Psychiat 1998; 43:92S
24. Mavissakalian M, Michelson L: Two-year follow-up of exposure and imipramine treatment of agoraphobia. Am J Psychiat 1986; 143:1106-1112
25. Lelliott PT, Marks IM, Monteiro WO, et al.: Agoraphobia 5 years after imipramine and exposure outcome and predictors. J Nerv Ment Dis 1987; 175:599-605
26. Williams SL, Falbo J: Cognitive and performance-based treatments for panic attacks in people with varying degrees of agoraphobic disability. Behav Res Ther 1996; 34(3):253-264
27. Clark DM, Salkovskis PM, Hackman A, et al.: A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiat 1994; 164:759-769
28. Mavissakalian M: Agoraphobia. In: Beitman BD, Klerman GL, eds. Integrating Pharmacotherapy and Psychotherapy. Washington: American Psychiatric Press; 1991:165-182
29. Barlow DH, Shear MK, Gorman JM, Woods SW: First line treatment of panic disorder - cognitive behavior treatment vs. imipramine vs. their combination: A multi-center study. Presented in NCDEU 38th annual program, Boca Raton, June 10-13, 1998